Cue Biopharma Stock Price Prediction
| CUE Stock | USD 1.22 0.13 11.93% |
Oversold Vs Overbought
50
Oversold | Overbought |
EPS Estimate Next Quarter (0.08) | EPS Estimate Current Year (0.76) | EPS Estimate Next Year (0.57) | Wall Street Target Price 3.6 | EPS Estimate Current Quarter (0.19) |
Using Cue Biopharma hype-based prediction, you can estimate the value of Cue Biopharma from the perspective of Cue Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Cue Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Cue because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Cue Biopharma after-hype prediction price | USD 1.25 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Cue |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cue Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cue Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Cue Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cue Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cue Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cue Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Cue Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cue Biopharma's historical news coverage. Cue Biopharma's after-hype downside and upside margins for the prediction period are 0.06 and 13.34, respectively. We have considered Cue Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cue Biopharma is dangerous at this time. Analysis and calculation of next after-hype price of Cue Biopharma is based on 3 months time horizon.
Cue Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Cue Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cue Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cue Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.44 | 11.99 | 0.03 | 0.01 | 8 Events / Month | 6 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.22 | 1.25 | 2.46 |
|
Cue Biopharma Hype Timeline
On the 28th of November Cue Biopharma is traded for 1.22. The entity has historical hype elasticity of 0.03, and average elasticity to hype of competition of -0.01. Cue is anticipated to increase in value after the next headline, with the price projected to jump to 1.25 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 2.46%, whereas the daily expected return is currently at 1.44%. The volatility of related hype on Cue Biopharma is about 137028.57%, with the expected price after the next announcement by competition of 1.21. Cue Biopharma has 14.7 M in debt with debt to equity (D/E) ratio of 0.33, which is OK given its current industry classification. Considering the 90-day investment horizon the next anticipated press release will be in about 8 days. Check out Cue Biopharma Basic Forecasting Models to cross-verify your projections.Cue Biopharma Related Hype Analysis
Having access to credible news sources related to Cue Biopharma's direct competition is more important than ever and may enhance your ability to predict Cue Biopharma's future price movements. Getting to know how Cue Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cue Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IKNA | Ikena Oncology | (0.05) | 4 per month | 0.00 | (0.13) | 1.80 | (1.74) | 5.87 | |
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.19) | 6.21 | (9.35) | 34.87 | |
| HCWB | HCW Biologics | 0.33 | 4 per month | 8.25 | 0.08 | 22.00 | (16.67) | 352.85 | |
| TPST | Tempest Therapeutics | (0.47) | 4 per month | 0.00 | (0.12) | 6.38 | (8.53) | 29.55 | |
| SCPH | Scpharmaceuticals | (0.03) | 8 per month | 0.00 | (0.15) | 4.30 | (7.09) | 20.70 | |
| MIST | Milestone Pharmaceuticals | 0.01 | 6 per month | 1.57 | 0.1 | 7.19 | (2.11) | 18.66 | |
| MCRB | Seres Therapeutics | (0.06) | 9 per month | 5.57 | 0.04 | 10.84 | (9.78) | 28.84 | |
| LUMO | Lumos Pharma | (0.05) | 6 per month | 2.95 | 0.02 | 5.95 | (5.19) | 16.25 |
Cue Biopharma Additional Predictive Modules
Most predictive techniques to examine Cue price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cue using various technical indicators. When you analyze Cue charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Cue Biopharma Predictive Indicators
The successful prediction of Cue Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cue Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cue Biopharma based on analysis of Cue Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Cue Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cue Biopharma's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 76.77 | 16.78 | 112.89 | 99.03 | PTB Ratio | 5.4 | 1.55 | 3.26 | 3.09 |
Story Coverage note for Cue Biopharma
The number of cover stories for Cue Biopharma depends on current market conditions and Cue Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cue Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cue Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Cue Biopharma Short Properties
Cue Biopharma's future price predictability will typically decrease when Cue Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cue Biopharma often depends not only on the future outlook of the potential Cue Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cue Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 45.8 M | |
| Cash And Short Term Investments | 48.5 M |
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |